##gff-version 3
##sequence-region Q06413 1 473
Q06413	UniProtKB	Chain	1	473	.	.	.	ID=PRO_0000199433;Note=Myocyte-specific enhancer factor 2C	
Q06413	UniProtKB	Domain	3	57	.	.	.	Note=MADS-box;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00251	
Q06413	UniProtKB	DNA binding	58	86	.	.	.	Note=Mef2-type;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q06413	UniProtKB	Region	271	278	.	.	.	Note=Beta domain	
Q06413	UniProtKB	Region	368	399	.	.	.	Note=Transcription repressor	
Q06413	UniProtKB	Compositional bias	4	31	.	.	.	Note=Lys-rich (basic)	
Q06413	UniProtKB	Compositional bias	146	183	.	.	.	Note=Ser-rich	
Q06413	UniProtKB	Site	432	433	.	.	.	Note=Cleavage;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q06413	UniProtKB	Modified residue	4	4	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q8CFN5	
Q06413	UniProtKB	Modified residue	59	59	.	.	.	Note=Phosphoserine%3B by CK2;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q8CFN5	
Q06413	UniProtKB	Modified residue	98	98	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q8CFN5	
Q06413	UniProtKB	Modified residue	106	106	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q8CFN5	
Q06413	UniProtKB	Modified residue	110	110	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q8CFN5	
Q06413	UniProtKB	Modified residue	116	116	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Modified residue	119	119	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Modified residue	222	222	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
Q06413	UniProtKB	Modified residue	228	228	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
Q06413	UniProtKB	Modified residue	234	234	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Modified residue	239	239	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Modified residue	240	240	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
Q06413	UniProtKB	Modified residue	252	252	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Modified residue	264	264	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Modified residue	293	293	.	.	.	Note=Phosphothreonine%3B by MAPK14;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:9069290,ECO:0000269|PubMed:9384584;Dbxref=PMID:9069290,PMID:9384584	
Q06413	UniProtKB	Modified residue	300	300	.	.	.	Note=Phosphothreonine%3B by MAPK14;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:9069290,ECO:0000269|PubMed:9384584;Dbxref=PMID:9069290,PMID:9384584	
Q06413	UniProtKB	Modified residue	396	396	.	.	.	Note=Phosphoserine%3B by CDK5;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15340086;Dbxref=PMID:15340086	
Q06413	UniProtKB	Modified residue	419	419	.	.	.	Note=Phosphoserine%3B by MAPK7;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:9069290,ECO:0000269|PubMed:9384584;Dbxref=PMID:9069290,PMID:9384584	
Q06413	UniProtKB	Modified residue	445	445	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
Q06413	UniProtKB	Cross-link	391	391	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO);Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15743823,ECO:0000269|PubMed:16478538;Dbxref=PMID:15743823,PMID:16478538	
Q06413	UniProtKB	Alternative sequence	87	134	.	.	.	ID=VSP_043339;Note=In isoform 4. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|Ref.3	
Q06413	UniProtKB	Alternative sequence	87	134	.	.	.	ID=VSP_046251;Note=In isoform 6. TLRKKGLNGCDSPDPDADDSVGHSPESEDKYRKINEDIDLMISRQRLC->ALNKKENKGCESPDPDSSYALTPRTEEKYKKINEEFDNMIKSHKIP;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:17974005;Dbxref=PMID:17974005	
Q06413	UniProtKB	Alternative sequence	107	134	.	.	.	ID=VSP_045478;Note=In isoform 5. VGHSPESEDKYRKINEDIDLMISRQRLC->ALNKKENKGCESPDPDSSYALTPRTEEKYKKINEEFDNMIKSHKIP;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:17974005;Dbxref=PMID:17974005	
Q06413	UniProtKB	Alternative sequence	271	278	.	.	.	ID=VSP_006248;Note=In isoform 2%2C isoform 4%2C isoform 5 and isoform 6. Missing;Ontology_term=ECO:0000303,ECO:0000303,ECO:0000303,ECO:0000303;evidence=ECO:0000303|PubMed:17974005,ECO:0000303|PubMed:7679508,ECO:0000303|PubMed:8455629,ECO:0000303|Ref.3;Dbxref=PMID:17974005,PMID:7679508,PMID:8455629	
Q06413	UniProtKB	Alternative sequence	368	399	.	.	.	ID=VSP_006249;Note=In isoform 3. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:7679508;Dbxref=PMID:7679508	
Q06413	UniProtKB	Natural variant	36	36	.	.	.	ID=VAR_078228;Note=Probable disease-associated mutation found in a patient with infantile onset epileptic encephalopathy and autism spectrum disorder. S->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27864847;Dbxref=PMID:27864847	
Q06413	UniProtKB	Natural variant	39	39	.	.	.	ID=VAR_078621;Note=Probable disease-associated mutation found in a patient with infantile onset epileptic encephalopathy and autism spectrum disorder. C->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23708187;Dbxref=dbSNP:rs796052729,PMID:23708187	
Q06413	UniProtKB	Mutagenesis	116	116	.	.	.	Note=Reduced acetylation. Further reduction in acetylation%3B when associated with R-119. Complete loss of acetylation%2C 15%25 less transactivation activity and slightly reduced DNA binding%3B when associated with R-119%3B R-234%3B R-239%3B R-252 and R-262. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Mutagenesis	119	119	.	.	.	Note=Reduced acetylation. Further reduction in acetylation%3B when associated with R-119. Complete loss of acetylation%2C 15%25 less transactivation activity and slightly reduced DNA binding%3B when associated with R-116%3B R-234%3B R-239%3B R-252 and R-262. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Mutagenesis	234	234	.	.	.	Note=Reduced acetylation. Complete loss of acetylation%2C 15%25 less transactivation activity and slightly reduced DNA binding%3B when associated with R-116%3B R-119%3B R-239%3B R-252 and R-264. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Mutagenesis	239	239	.	.	.	Note=Reduced acetylation. Complete loss of acetylation%2C 15%25 less transactivation activity and slightly reduced DNA binding%3B when associated with R-116%3B R-119%3B R-234%3B R-252 and R-264. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Mutagenesis	252	252	.	.	.	Note=Reduced acetylation. Complete loss of acetylation%2C 15%25 less transactivation activity and slightly reduced DNA binding%3B when associated with R-116%3B R-119%3B R-234%3B R-239 and R-264. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Mutagenesis	264	264	.	.	.	Note=Reduced acetylation. Complete loss of acetylation%2C 15%25 less transactivation activity and slightly reduced DNA binding%3B when associated with R-116%3B R-119%3B R-234%3B R-239 and R-252. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15831463;Dbxref=PMID:15831463	
Q06413	UniProtKB	Mutagenesis	271	271	.	.	.	Note=No effect on transcriptional activation. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15834131;Dbxref=PMID:15834131	
Q06413	UniProtKB	Mutagenesis	272	272	.	.	.	Note=Reduced transcriptional activation. Completely abolishes transcriptional activation%3B when associated with N-273 and N-275. E->Q;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15834131;Dbxref=PMID:15834131	
Q06413	UniProtKB	Mutagenesis	273	273	.	.	.	Note=Reduced transcriptional activation. Completely abolishes transcriptional activation%3B when associated with Q-272 and N-275. D->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15834131;Dbxref=PMID:15834131	
Q06413	UniProtKB	Mutagenesis	275	275	.	.	.	Note=Reduced transcriptional activation. Completely abolishes transcriptional activation%3B when associated with Q-272 and N-273. D->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15834131;Dbxref=PMID:15834131	
Q06413	UniProtKB	Mutagenesis	293	293	.	.	.	Note=Abolishes MAPK14-mediated phosphorylation. No effect on MAPK7-mediated phosphorylation%3B when associated with A-300. T->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:9069290,ECO:0000269|PubMed:9384584;Dbxref=PMID:9069290,PMID:9384584	
Q06413	UniProtKB	Mutagenesis	300	300	.	.	.	Note=Abolishes MAPK14-mediated phosphorylation. No effect on MAPK7-mediated phosphorylation%3B when associated with A-293. T->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:9069290,ECO:0000269|PubMed:9384584;Dbxref=PMID:9069290,PMID:9384584	
Q06413	UniProtKB	Mutagenesis	387	387	.	.	.	Note=No change in transactivational activation for isoforms with or without the beta domain. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15834131;Dbxref=PMID:15834131	
Q06413	UniProtKB	Mutagenesis	391	391	.	.	.	Note=Abolishes sumoylation. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16478538;Dbxref=PMID:16478538	
Q06413	UniProtKB	Mutagenesis	396	396	.	.	.	Note=Abolishes sumoylation. Enhanced transcriptional activity. S->A%2CC;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15340086,ECO:0000269|PubMed:15834131,ECO:0000269|PubMed:16478538;Dbxref=PMID:15340086,PMID:15834131,PMID:16478538	
Q06413	UniProtKB	Mutagenesis	396	396	.	.	.	Note=No change in transactivational activation for isoforms with or without the beta domain. S->A;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15340086,ECO:0000269|PubMed:15834131,ECO:0000269|PubMed:16478538;Dbxref=PMID:15340086,PMID:15834131,PMID:16478538	
Q06413	UniProtKB	Mutagenesis	396	396	.	.	.	Note=No effect on sumoylation. No effect on transcriptional activity. S->E;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15340086,ECO:0000269|PubMed:15834131,ECO:0000269|PubMed:16478538;Dbxref=PMID:15340086,PMID:15834131,PMID:16478538	
Q06413	UniProtKB	Mutagenesis	419	419	.	.	.	Note=No effect on MAPK14-mediated phosphorylation. Abolishes MAPK7-mediated phosphorylation and reduces transactivation activity. S->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:9069290,ECO:0000269|PubMed:9384584;Dbxref=PMID:9069290,PMID:9384584	
Q06413	UniProtKB	Mutagenesis	432	432	.	.	.	Note=Abolishes cleavage by caspase 7. D->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11904443;Dbxref=PMID:11904443	
Q06413	UniProtKB	Sequence conflict	390	390	.	.	.	Note=I->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
